Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.

Forgot your password?

Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.

I agree to TheMaven'sTerms andPolicy

Already have an account? Login here

JIM CRAMER INVESTING PERSONAL FINANCE RETIREMENT TECHNOLOGY MARKETS HOW-TO VIDEO FINANCIAL ADVISOR CENTER

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

InMed To Participate At Virtual Conferences In January 2021

By PR Newswire
Jan 5, 2021 4:52 PM EST

InMed Announces Results Of Initial Phase 1 Clinical Trial Of INM-755 CBN Cream In Healthy Subjects

By PR Newswire
Nov 25, 2020 7:30 AM EST

InMed Pharmaceuticals And BayMedica Announce Collaboration For Manufacturing And Testing Of Novel Cannabinoid Therapeutics

By PR Newswire
Nov 18, 2020 7:30 AM EST

InMed Pharmaceuticals Announces The Closing Of US$8 Million Public Offering

By PR Newswire
Nov 16, 2020 11:42 AM EST

InMed Announces Pricing Of US$8M Public Offering And Listing On The Nasdaq Capital Market Under The Symbol "INM"

By PR Newswire
Nov 12, 2020 9:10 AM EST

InMed Announces Completion Of Subject Treatments In Second Phase 1 Clinical Trial Of INM-755 CBN Cream In Healthy Subjects

By PR Newswire
Sep 24, 2020 7:30 AM EDT

InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing

By PR Newswire
Sep 22, 2020 7:30 AM EDT

InMed Announces Completion Of Share Consolidation

By PR Newswire
Jun 30, 2020 6:18 PM EDT

InMed Announces Filing Of Registration Statement In Connection With United States Offering, Application To Seek Nasdaq Listing And Planned Share Consolidation

By PR Newswire
Jun 19, 2020 6:20 PM EDT

InMed To Present At Canaccord Genuity's 4th Annual Cannabis Conference

By PR Newswire
May 7, 2020 7:30 AM EDT

InMed And Almac Group Developing Improved Cannabinoid Production Methods

By PR Newswire
May 5, 2020 7:30 AM EDT

InMed Receives CTA Approval For Second Phase 1 Clinical Trial With INM-755

By PR Newswire
Apr 30, 2020 7:30 AM EDT

InMed Announces Completion Of Initial Phase 1 Clinical Trial Of INM-755 CBN Cream In Healthy Subjects

By PR Newswire
Apr 1, 2020 7:30 AM EDT

InMed Submits Clinical Trial Application To Evaluate INM-755 In Second Phase 1 Trial

By PR Newswire
Mar 24, 2020 7:30 AM EDT

InMed Provides Update On Operations In Response To The COVID-19 Global Outbreak

By PR Newswire
Mar 20, 2020 7:30 AM EDT

InMed Pharmaceuticals Announces Completed Enrollment In Phase 1 Clinical Trial Of INM-755 CBN Cream In Healthy Subjects

By PR Newswire
Mar 10, 2020 1:24 PM EDT

InMed Expands On Announcement Of Cannabinol (CBN) Therapeutic Leadership With New Website Content And CEO Interview

By PR Newswire
Jan 21, 2020 7:30 AM EST

InMed First To Advance Cannabinol (CBN) Into Therapeutic Clinical Trials

By PR Newswire
Jan 20, 2020 7:30 AM EST

InMed Pharmaceuticals To Attend And Exhibit At EB2020 World Congress

By PR Newswire
Jan 16, 2020 7:30 AM EST

InMed Pharmaceuticals To Present At The Biotech Showcase Conference

By PR Newswire
Jan 8, 2020 2:30 AM EST

InMed Receives Clinical Trial Application Approval For INM-755, A Rare Cannabinoid Formulation Under Development For The Treatment Of Epidermolysis Bullosa

By PR Newswire
Dec 9, 2019 7:30 AM EST

Terms Of Use
Privacy Policy
Advertise
Reprints
Customer Service
Data
Topic Archive
Subscriptions

© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.